跳转至内容
Merck
CN

1448901

USP

莫匹罗星

United States Pharmacopeia (USP) Reference Standard

别名:

5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester, BRL 4910A, Pseudomonic acid

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H44O9
CAS号:
分子量:
500.62
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

mupirocin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O

InChI

1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

InChI key

MINDHVHHQZYEEK-HBBNESRFSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

生化/生理作用

Antibiotic; inhibits isoleucyl-tRNA synthetase (IRS).

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M E H Jaspers et al.
Burns : journal of the International Society for Burn Injuries, 40(8), 1570-1574 (2014-04-02)
Staphylococcus aureus wound colonization frequently occurs in patients with burns and can cause impaired wound healing. Nasal mupirocin application may contribute to the reduction of burn wound colonization of endogenous origin, whereas colonization by the exogenous route can be reduced
Christopher M Thomas et al.
Nature reviews. Microbiology, 8(4), 281-289 (2010-03-02)
Mupirocin, a polyketide antibiotic produced by Pseudomonas fluorescens, is used to control the carriage of methicillin-resistant Staphylococcus aureus on skin and in nasal passages as well as for various skin infections. Low-level resistance to the antibiotic arises by mutation of
Miranda M L van Rijen et al.
The Journal of antimicrobial chemotherapy, 61(2), 254-261 (2008-01-05)
The majority of nosocomial Staphylococcus aureus infections originate from the patients' own flora, with nasal carriage of S. aureus before surgical procedures being a risk factor for subsequent infection. The objective of this review was to assess whether intranasal mupirocin
Alexander J Kallen et al.
Infection control and hospital epidemiology, 26(12), 916-922 (2006-01-19)
To review the evidence evaluating perioperative intranasal mupirocin for the prevention of surgical-site infections according to type of surgical procedure. Systematic review and meta-analysis of published clinical trials. Studies included were either randomized clinical trial or prospective trials at a
Andie S Lee et al.
Journal of clinical microbiology, 52(10), 3749-3754 (2014-08-15)
Topical mupirocin is widely used for the decolonization of methicillin-resistant Staphylococcus aureus (MRSA) carriers. We evaluated the capacity of various MRSA clonotypes to develop mutations in the ileS gene associated with low-level mupirocin resistance. Twenty-four mupirocin-sensitive MRSA isolates from a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门